PSY93 - COST EFFECTIVENESS OF LETERMOVIR AS PROPHYLAXIS OF CLINICALLY SIGNIFICANT CYTOMEGALOVIRUS REACTIVATION AND DISEASE IN ADULT CMV-SEROPOSITIVE ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT- AN ENGLISH PAYER PERSPECTIVE
Abstract
Authors
C. Brown A. Mayes J. Schelfhout Y. Jiang M. Glover E. Taymor